echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > New RCTs for the treatment of acute ischaemic stroke with ginkgolide injection released

    New RCTs for the treatment of acute ischaemic stroke with ginkgolide injection released

    • Last Update: 2023-01-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On October 28, 2022, the "RCT New Evidence for Antiplatelet Treatment of Ginkgolide Acute Ischemic Stroke" live broadcast satellite meeting, hosted by the Shanghai Stroke Society and co-organized by Chengdu Baiyu Pharmaceutical, was successfully concluded during the 3rd Annual Conference of the Shanghai Stroke Society
    .
    The conference was chaired by Professor Dong Qiang of Huashan Hospital affiliated to Fudan University, Professor Lou Min of the Second Affiliated Hospital of Zhejiang University School of Medicine, and Dr.
    Dong Yi of Huashan Hospital affiliated to Fudan University as speakers, three neurologists and many neurologists in China gathered in the cloud to discuss the clinical exploration of antiplatelet therapy for acute ischemic stroke, and the cumulative number of viewers of the live broadcast reached more than 1830 people
    .
    The evidence-based evidence of the new RCT of ginkgolide was released under the joint witness of many experts and attracted the attention
    of many neurologists in the industry.

    At the beginning of the conference, Professor Dong Qiang of Shanghai Huashan Hospital affiliated to Fudan University delivered an opening speech, introducing the overview of two RCT trials of ginkgolide injection, affirming the efficacy of ginkgolide injection, and believing that its application in the acute phase of ischemic stroke has broad prospects and great prospects.

    Focus on clinical research

    Ginkgolide effectively improves neurological deficits in stroke patients

    In the first part of the conference, Dr.
    Dong Yi introduced
    the "Effectiveness of Ginkgolide in the Treatment of Acute Ischemic Stroke with Aortic Atherosclerosis", which included 936 cases and 61 centers, and Ginkgolide injection through the new pathway of PAF mechanism can effectively improve neurological defects and clinical outcomes in patients with acute ischemic stroke complicated with atherosclerosis, and the sooner it is used, the better
    the prognosis.



    Click on the video below to watch Dr.
    Yi Dong's "Study on the effectiveness of ginkgolide in the treatment of acute ischemic stroke with atherosclerosis"



    A study of the effectiveness of ginkgolide in the treatment of acute ischemic stroke complicated with atherosclerosis, published in CNS Neuroscience & Therapeutics in 2021
    .

    Interpreting the GIANT trial

    Ginkgolide significantly improves clinical outcomes in stroke patients

    In the second part of the conference, Professor Lou Min introduced in detail "Combination Therapy" of "Hyperacute Reperfusion Therapy for Cerebral Infarction"
    .
    Focusing on "Current Status of Acute Stroke Reperfusion Treatment
    and Ginkgolide GIANT Test", Professor Lou introduced the indispensable advantages of Ginkgolide injection in acute stroke reperfusion treatment, and shared the medication experience and medication experience of Ginkgolide injection
    .


    Click the video below to watch Professor Lou Min's "Combination Therapy" of Hyperacute Reperfusion Therapy for Cerebral Infarction

    1.
    Current status of reperfusion therapy for acute stroke

    At present, the most important treatment for ischemic thrombolysis is reperfusion therapy, including intravenous thrombolysis and mechanical thrombectomy, but nearly 50% of patients do not achieve good clinical outcomes
    .

    Neuroprotection offers hope for improved outcomes in patients with reperfusion, which regulates and improves cell function
    through a series of biochemical metabolic changes.
    But for many years, there have been some obstacles to the clinical transformation of neuroprotection, from the early years of anti-free radicals, to uric acid, magnesium sulfate, to the combination of some immune agents, so far, no neuroprotective drug has been approved by the FDA for the treatment
    of AIS.

    In response to this situation, the Stroke Treatment Academic Industry Roundtable (STAIR) was established in the United States to regularly discuss clinical trial studies of acute ischemic stroke, and the strategy has begun to work
    .
    This strategy suggests that neuroprotective therapy needs to be combined with reperfusion therapy; After recirculation and reperfusion of blood flow, with neuroprotective agents, better results can be obtained; Neuroprotective agents are preferably drugs
    with multi-target therapeutic effects.
    During the entire chain reaction process, if only a certain point is targeted, effective protection may not be achieved
    .

    2.
    GIANT trial interpretation
    GIANT is a clinical study on thrombolysis combined with neuroprotection, including 1113 ischemic stroke patients
    in 24 centers.

    Trial methods: Randomized into 2 groups, the treatment group was ginkgolide injection treatment group, through 7 days of treatment, 3 months follow-up; The control group used normal saline
    .

    Observations: difference in NHISS scores at 24 hours; 7-day efficiency and safety results for NIHSS; At 90 days, the difference
    in Rankin scores between the two groups.

    GIANT test results

    1.
    Ginkgolide injection significantly improved the clinical outcome of patients with acute ischemic stroke at 90 days;

    2.
    Ginkgolide injection effectively improves neurological function in the early treatment of acute ischemic stroke;

    3.
    On the basis of the standard treatment of acute ischemic stroke, the use of ginkgolide in the first 24 hours after IVT
    is safe, does not increase the risk of bleeding, and may improve the prognosis;

    4.
    Ginkgolide combined with alpeplase treatment may be the recommended treatment for patients in the first 24 hours after IVT
    .


    The study was published in the journal Front Pharmacol in 2021
    .

    Introduction of ginkgolide injection

    1.
    The only natural molecular compound drug containing high-purity ginkgolide ABC and white fruit lactone

    Ginkgolide injection directly targets the clinical pain point and is the only natural molecular compound drug
    containing high-purity ginkgolide ABC and white fruitolactone.

    2.
    There is high-level evidence-based evidence throughout the course of ischemic stroke disease

    Ginkgolide injection has high-level evidence-based evidence in the whole process of ischemic stroke disease, which is worthy of clinical promotion and application
    .

    New evidence from the Ginkgolide RCT provides a safe and effective new treatment for
    acute ischaemic stroke.
    Ginkgolide injection is an antiplatelet-binding neuroprotective, double-effect product, safe, effective, high pharmacoeconomic value, suitable for the whole treatment of ischemic stroke, worthy of high attention
    of neurologists.

    Expert profiles

    Professor Dong Qiang

                              

    • Professor, doctoral supervisor

    • Shanghai Leading Talents Top 10 Public Health Workers in Shanghai

    • Director of Department of Neurology, Huashan Hospital, Fudan University

    • Deputy Director of the National Medical Center for Neurological Diseases (Huashan).

    • Vice Chairman of the Neurology Branch of the Chinese Medical Association, Vice President of the Chinese Stroke Society

    • Chairman of the Neurology Committee of Shanghai Medical Association, President of the Neurologist Branch of Shanghai Medical Doctor Association

    • Director of Shanghai Clinical Medical Center for Neurological Diseases, Director of Shanghai Quality Control Center of Neurology

    • Executive Vice President of Shanghai Stroke Society




    Professor Lou Min


    • Professor of Zhejiang University, chief physician, doctoral supervisor

    • Deputy Dean of Zhejiang University School of Medicine

    • Deputy Director of the Department of Neurology, The Second Affiliated Hospital of Zhejiang University School of Medicine

    • Deputy Director of the Institute of Brain Medicine, Zhejiang University

    • Director of the Chinese Stroke Society

    • Vice Chairman of the Medical Quality Branch of the Chinese Stroke Society

    • Member of the Cerebrovascular Group of the Neurology Branch of the Chinese Medical Association

    • Chairman-elect of the Neurology Branch of Zhejiang Medical Association

    • Vice Chairman of the Youth Committee of the Stroke Prevention and Control Project of the National Health and Family Planning Commission

    • Secretary General of Zhejiang Stroke Society


    Dr.
    Yi Dong


    • Doctor of Medicine, graduated from Fudan University, currently mainly responsible for the cerebrovascular fusion ward of Hongqiao Campus of Huashan Hospital affiliated to Fudan University

    • He has studied at OSF/INI Comprehensive Stroke Clinic in the United States and Oxford University in the United Kingdom

    • From 2018 to 2019, he was trained in the International Clinical Investigator Training Program at Harvard University

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.